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Successful  stimulation of human  resting  T  cells,  stimulation  leading to  cell 
proliferation,  classically requires  two  distinct signals.  Signal one,  delivered  by 
antigen, lectin, or mAb directed against the antigen receptor complex, T3/Ti, 
alone is not sufficient unless the second, usually accessory cell derived signal is 
provided.  With  lectin  (1)  and  CD3  antibody  (2-4),  but  not  with  antigen  (5) 
stimulation, signal two can be substituted by PMA (6). 
Apart from triggering via T3/Ti, an alternative pathway of T  cell activation 
has recently been  described (7). A  combination of two mAb detecting distinct 
epitopes on the sheep erythrocyte receptor (E-receptor, CD2 structure) can lead 
to vigorous T  cell proliferation (7). In this system, the first antibody induces the 
expression of a thus-far hidden epitope on the E-receptor and makes it accessible 
to the second antibody, again a two-signal nature is evident. 
In this paper,  we show that, for stimulation via this alternative pathway, one 
signal may be substituted by PMA. T  cells cultured in the presence of PMA can 
be stimulated by some but not all CD2 mAb. While T  cell stimulation via either 
the CD2 or the CD3 structure has recently been causally linked to a concomitantly 
observed  elevation  of intracellular  Ca  ++  levels  (8-11),  in  our  system,  T  cell 
growth occurs without an apparent change in intracellular Ca  ++. 
Materials and Methods 
MonoclonaIAntibodies.  VIT3 detects an epitope on the T3 membrane structure (CD3). 
Immune precipitation revealed as its target a  19-29 kD protein complex. It comodulates 
with OKT3 (Ortho Diagnostics,  Raritan, N  J), T3 (Coulter Immunology, Hialeah, FL), 
and anti-Leu-4 (Becton Dickinson  Monoclonal Center, Mountain View, CA), and has the 
same  cellular distribution of reactivity. The antibody was obtained after immunizing 
BALB/c mice with purified T cells, and was generated essentially as previously described 
(12). 
VIT13 was obtained after immunizing with PHA blasts. It detects an epitope on the E- 
receptor, hidden on resting T cells but strongly exposed after in vitro stimulation (13). A 
detailed characterization of this antibody will be published (Stockinger, manuscript in 
preparation). 
Other mAbs used in this study were VIP1  (transferrin receptor) (13),  VIDI  (Ia/Dr) 
(13),  OKTll  (Ortho  Diagnostics),  Tll  (Coulter  Immunology), BMA  0110  (Behring 
Corp., Marburg, Federal Republic of Germany), 9.6 (kindly provided by Dr. P. Martin, 
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Seattle,  WA) (14), X11 (T11, type, kindly provided by Dr. A. Bernard, Villejuif,  France), 
and the anti-IL-2-R antibody, anti-Tac (kindly provided by Dr. T. Waldmann, National 
Institutes of Health, Bethesda, MD (15). 
Purification ofT Cells.  T cells were separated by rosetting with neuraminidase-treated 
SRBC, and by density gradient centrifugation (Ficoll-Hypaque, Pharmacia Fine Chemicals, 
Uppsala, Sweden). Cells from the interphase were collected and are referred to as non-T 
cells. After lysis of rosetted SRBCs, T cells obtained from the pellet were further depleted 
of accessory cells by plastic adherence, nylon wool adherence, and treatment with anti-Ia 
(Q5/13, kindly provided by Dr. Vito Quaranta, Scripps Clinic and Research Foundation, 
La Jolla, CA), and antimonocyte (VIM13) (16)  mAb plus complement. The resulting T 
cell  preparation  contained <0.5%  monocytes, as estimated  by indirect immunofluores- 
cence on a FACS 440 cell sorter.  Unless  supplemented with non-T cells, this population 
only marginally responded to PHA, PMA, or CD3 antibody stimulation. 
Proliferative Assays.  PHA (Wellcome,  Beckenham,  United  Kingdom) was  used  at a 
final concentration of 2 t~g/ml. PMA (Sigma Chemical Co., St. Louis, MO) was dissolved 
in ethanol at 10 mg/ml, diluted 1:10 with RPMI 1640, and stored at -30 °C. Immediately 
before use, the material was thawed and used at a final concentration of 50 ng/ml, unless 
otherwise indicated. For stimulation, the mAbs were used at 10 #g/ml or a  1:100-1:400 
dilution of ascitic fluid if the protein content was not available. 
Cultures were set up in  U-bottomed microwells (Nunc, Roskilde, Denmark) in a final 
volume of  120  tal. The  medium  was  RPMI  1640  (Gibco,  Paisley,  United  Kingdom) 
containing  10%  FBS  (Flow  Laboratories,  Beckenham,  United  Kingdom),  L-glutamine, 
and antibiotics. The cultures were incubated in a humidified atmosphere with 5% CO2 at 
37°C for 96 h.  1 #Ci/well [SH]thymidine (New England Nuclear, Boston, MA) was added 
18 h before harvest. The incorporated radioactivity was collected on glass fiber filters and 
counted in a liquid scintillation  counter. Values are given as cpm ± SE (× 10  -s) of triplicate 
cultures. 
Phenotypic Analysis of Stimulated  T Cells.  Purified T  cells, at a density of 106 cells/ml, 
were cultured in the presence of 50 ng/ml PMA for 48 h. The cells were harvested and 
stained with antibodies as indicated in Fig.  2. The binding of the antibodies was assessed 
by standard indirect immunofluorescence techniques and evaluated on a  FACS 440 cell 
sorter (Becton Dickinson Immunocytometry Systems,  Sunnyvale, CA), essentially  as pre- 
viously described (13). 
Determination of Cytoplasmic Ca ++ Levels.  Purified T  cells were loaded by incubation 
with Quin2 acetoxymethyl ester (Quin2/AM; Amersham International, Buckinghamshire, 
United  Kingdom) following the  method of Tsien  et  al.  (8)  with  slight  modifications. 
Briefly,  5 ×  107 cells were incubated with  50 tal of a  1 mM Quin2 stock solution in 5 ml 
RPMI 1640 with 10% FBS for 30 min at 37 °C. Subsequently, the suspension was diluted 
fourfold and incubated 30 min more. The cells were then spun down gently, resuspended 
in fresh RPMI 1640 with FBS, and kept in the dark at 37°C. Immediately before use,  1.5 
X  10 7 cells were spun down, resuspended in 2.5 ml of simplified  medium (145 mM NaCI, 
5 mM KCI, 1 mM Na2HPO4,  1 mM CaCI2, 0.5 mM MgSO4, 5 mM glucose, 10 mM Hepes 
dissolved  in  double distilled  water and  titrated  with  NaOH to pH  7.40 at  37°C),  and 
transferred  to  prewarmed quartz cuvettes.  Fluorescence intensity  was recorded on an 
Aminco spectrofluorometer SPF 500 (Aminco Inc., Silver Spring, MD) set on ratio mode 
with excitation at 339 nm and emission at 492 nm (1- and 5-nm bandwidths). The cuvette 
was constantly kept at 37 °C and the cell suspension was continuously stirred. All reagents 
(Con A; Pharmacia Fine Chemicals; VIT3, 9.6, VIT13, and PMA) were prepared as 100- 
fold concentrated  stock  solution  and  added  in  25  /A aliquots.  Maximum  fluorescence 
values (F,,,x) were determined by adding I 0 ~M of the heavy metal chelator diethylenetria- 
minepentaacetic acid (DTPA) (Sigma Chemical Co.) and lysing the cells with 0.1% Triton 
X-100 (Serva,  Heidelberg, Federal Republic of Germany). Subsequently, minimum fluo- 
rescence (F,,i,) was determined by adding 0.5 mM MnCI2. 656  T  CELL  STIMULATION  VIA  THE  ERYTHROCYTE  RECEPTOR 
TABLE  I 
Purified T Cells Proliferate in Response to Certain Antibody and Antibody 
Plus PMA Combinations 
First reagent 
[3H]Thymidine incorporation (cpm ×  10  -3 ±  SE) in 
response to second reagent 
Medium  VIT 13  PMA 
OKTll  0.4±0.1  1.4±0.7  2.1  ±0.8 
Tll  0.9±0.5  1.3±0.7  2.0±  1.7 
BMA 0110  0.4 ±  0.1  0.8 ±  0.4  1.7 ±  0.6* 
9.6  0.6 ±  0.2  25.4 ±  7.7*  15.6 ±  2.9* 
Xll  0.5±0.1  36.8±8.1'  26.6±6.7* 
VIT13  0.3 ±  0.1  0.4 ±  0.1  28.1  ±  3.7* 
VIT3  0.4 ±  0.1  0.4 ±  0.1  46.8 ±  7.7* 
--  0.3  ±  0.1  0.3 ±  0.1  2.6 ±  1.2 
n  -- 3 except for *n -- 5 and* n  =  8. 
Results 
Certain CD2 Antibodies Are Comitogenic with PMA.  mAb against the E-receptor 
can have functionally adverse effects. While antibodies to the SRBC binding site 
of the E-receptor were found to inhibit various T  cell functions (17-22),  com- 
binations (antibody pairs) of antibodies directed against determinants  unrelated 
to the SRBC binding site can induce intense T  cell proliferation (7). 
When evaluating the effect of several CD2 antibodies on T  cell DNA replica- 
tion, we also found a clearcut pattern,  in that several antibodies (OKT11, T11, 
BMA0110) could not stimulate T  ceils together with our antibody, VIT 13, while 
9.6 and X 11 served as potent costimulatory reagents (Table I). 
As far as the previously observed (7) correlation between fine specificity and 
functional  effect of these  antibodies  is  concerned,  the  9.6  antibody  does  not 
seem to follow the rules mentioned above in that it inhibits E-rosette formation 
(14) but nevertheless stimulates T  cells in the presence of certain mAb submitted 
for the Second International Workshop on Human Leucocyte Antigens in Boston 
(23, 24), and is strongly comitogenic with VIT 13 and together with PMA (Table 
I). 
Interestingly enough,  those CD2 antibodies that were comitogenic with each 
other (9.6, X 11, VIT 13) turned out to be also comitogenic with PMA, while the 
CD2  antibodies  that  were  not  comitogenic  with  VIT13  (OKTll,  Tll, 
BMA0110) were not comitogenic with PMA either (Table I). 
The kinetics of the proliferative response induced by the antibody VIT13 in 
the  presence  of  PMA  is  shown  in  Fig.  1,  in  comparison  to  simultaneously 
measured reactions to PHA and VIT3 antibody (CD3) plus PMA. This anti-T3 
antibody,  although  nonmitogenic  with  resting  mononuclear  cells,  and  even  a 
potent inhibitor  of lectin  and  antigen  stimulation,  also proved to be a  potent 
stimulating reagent in the presence of PMA (Table I) (4). Maximum proliferation 
in all three systems is seen between days 4 and 5. Dilution experiments revealed 
that  relatively  high  concentrations  of VITI3  (0.4-10  #g/ml)  are  needed  for 
stimulation, while PMA is effective at a wide range of concentrations, from 0.005 
to 5 ug/ml (Table II). 13 
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FIGURE  1.  Time course of proliferation of purified T  cells stimulated by VIT13 plus PMA 
(O), VIT3 plus PMA (ll), or PHA ((3). For PHA stimulation, T  cell cultures were supplemented 
with  1% non-T cells. The cultures were labelled with [SH]thymidine as described in Materials 
and Methods, and harvested 18 h  later at time points indicated. 
TAnLE II 
T Cell Proliferation in Dose-dependent Manner in Response to VIT13 Plus PMA 
Stimulants  [SH]Thymidine incorporation (cpm x 10  -~ -+ SE) in 
response to: 
VIT13  PMA + 10 #g/ml  VIT13  + 50 
PMA (ng/ml)  (#g/ml)  PMA alone  V  IT 13  ng/ml PMA 
5,000  50  9.6 ±  0.5  38,1  +  1.1  36.0 +  0.6 
500  10  7.3 ±  0.2  28.9 +  0.2  25.2 4- 1.3 
50  2  4.2 -+ 0.6  22.5 +  1.8  15.6 -+ 1.5 
5  0.4  0.6-.+0.1  6.1  -+2.8  11.7-+2.4 
0.5  0.08  0.3 -  0.1  1.6 ±  1.2  4.9 -+ 0.8 
--  --  0.4 -+ 0.1  0.9 ±  0.1  5.1 -+ 0.5 
PMA Induces Expression of the VIT13 Determinant.  The fact that VIT13 does 
not seem to react with resting T  cells but nevertheless induces T  cell proliferation 
in the presence of PMA raised the question of whether PMA induces expression 
of the VIT13 determinant.  As shown in Fig. 2, this is indeed the case. After 48 
h  of culture,  75% of PMA-stimulated T  cells are VIT13 +, in contrast to 6% of 
ceils  cultured  in  medium  alone.  Staining  by  9.6  antibody,  clearly  visible  on 
resting cells, was strongly enhanced, indicating that the number of binding sites 
for this antibody increased considerably.  As estimated by forward light scatter 
during FACS analysis, the cell sizes also increased in response to PMA treatment 
(data not shown). It is therefore possible that the enhancement of 9.6 fluorescence 
may not necessarily reflect a  higher antigen  density (per square micrometer of 
cell  surface),  but  possibly  a  net  increase  correlating  to  blast  formation.  No 
exposure of another activation antigen,  the transferrin  receptor, as seen by the 
VIP 1 antibody, was observed. Our observations confirmed previous reports (25) 
that the T3 structure is downregulated by PMA (Fig. 2). 
Anti-Tac  mAb  Inhibits  T  Cell  Proliferation  Induced  by  CD2  Antibodies  Plus 
PMA.  Table III shows that the proliferation induced by VIT13 plus PMA, as 658  T  CELL  STIMULATION  VIA  THE  ERYTHROCYTE  RECEPTOR 
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FIGURE 2.  Effect of PMA on the expression of T cell surface markers. After 48 h of culture 
in the presence of 50  ng/ml PMA (P) or medium alone (M), the cells were harvested and 
stained with either VIT13  (CD2),  9.6  (CD2),  VIP1  (transferrin receptor), or VIT3  (CD3) 
antibodies. The graphs displayed were obtained by logarithmic amplification. The smoothed 
line represents the negative control curve. 
TABLE  III 
Anti-Tac Antibody Inhibits Proliferation of Costimulated T Cells 
Stimulus 
[SH]Thymidine  incorporation  (cpm × 10  -3 4- SE) in re- 
sponse to added antibody 
None  Anti-Tat  Control (V1D1) 
PHA*  44.4 4- 1.4  33.8 4- 2.6  47.9 4- 3.5 
VIT3 +  PMA  42.4 4- 4.7  27.4 4- 2.6  45.5 4- 2.5 
V1TI3 +  PMA  29.0 4- 0.7  4.9 --. 1.2  27.0 4- 3.2 
--  0.94-0.1  1.54-0.8  2.1  4- 1.3 
* Supplemented with 1% non-T cells 
well as that of PHA and of VIT3 plus PMA-stimulated T  cells  is substantially 
inhibited in the presence of the IL-2-R antibody anti-Tac.  Under these condi- 
tions, the DNA synthesis of T  cells  stimulated by VIT13 plus PMA is reduced 
by 80%.  The addition of high concentrations of an unrelated control antibody 
(VID 1) has no effect. Therefore, the cell growth seen after VIT 13 antibody plus 
PMA stimulation seems to follow the classical  IL-2-dependent pathway of T  cell 
activation (26). 
CD2  Antibodies  Plus  PMA  Stimulate  T  Cell  Proliferation  Without  Measurable 
Changes oflntracellular  Ca ++ Levels.  It has recently been reported that stimu- 
lation of resting T  cells  with lectins (8),  CD3 antibodies (27),  and certain CD2 
antibody combinations (9) is followed by a rapid elevation of intracellular Ca  ++ 
levels.  Our studies confirm these observations (Fig,  3,  Table  IV).  Con A, at a 
dose optimal for mitogenesis (10 ~g/ml) changes Ca  ++ levels from 112  4-  12 nM 
to 406 4- 59 nM (mean increase, 3.5 4- 0.3-fold, n =  5) within 2 rain after being 
added to the ceil suspension. A similar reaction is observed with the nonmitogenic 
CD3 antibody VIT3.  There, the Ca  ++ levels rise from 151  4-  11  nM to 304  4- 
28 nM (mean increase 1.9 4- 0.1-fold). In addition, the combination of the CD2 
antibodies 9.6 or X11  plus VIT13 leads to an increase of Ca  ++ levels from 142 
+  16 nM to 534 4-  158 nM (mean increase 3.7 4- 0.9-fold, n =  4) (Fig. 3, Table 
iv). 
None of the investigated CD2 antibodies alone, however, be they stimulatory HOLTER  ET  AL.  659 
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Measurement of free cytoplasmic  Ca**. Purified T cells were loaded with Quin2  FIGURE  3. 
and their fluorescence intensity was recorded on an Aminco spectrofluorometer SPF 500 in 
response to Con A  (10 #g/ml),  VIT3,  9.6,  and  VITI3  antibodies (10 vg/m|) and PMA (50 
ng/ml). 
TABLE IV 
Rise in Free Cytoplasmic Ca  ++ in Response to Lectin 
and Antibody Stimuli 
Mitogen  Increase  n 
(10 ug/ml) 
Con A  3.5 _+ 0.3  5 
VIT3  1.9 _+ 0.1  5 
9.6/X11 + VITI3  3.7 +_ 0.9  4 
Values are expressed as x-fold increase measured 3 rain after  mitogen 
addition. Resting Ca  ++ levels were determined to be 132 nM _+ 6 (n = 14). 
with PMA or not, leads to changes in Ca  ++ as measured by Quin2.  No increase 
was  observed  when  these  antibodies  were  used  in  the  presence  of even  high 
concentrations (50-5,000 ng/ml) of PMA (Fig.  3). Similarly, the addition of 9.6 
or VIT13 to T  cells, preincubated with PMA for 4 or 24 h, caused no apparent 
change in Ca  ++ levels (data not shown). As evident from these data,  PMA alone 
did not raise Ca  ++ levels either, which is also in agreement with previous reports 
(8,  28).  On the other hand, it did not lead to unresponsiveness of T  cells in this 
system, since  Con  A  (Fig.  3) and  the  combination of VIT13 plus  9.6  or  Xll 
(data not shown) still  induced an influx of Ca  ++ ions in T  cells pretreated  with 
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Discussion 
In the course of our studies, we found that certain CD2 antibodies can induce 
proliferation  of resting  T  cells  in  the  presence  of  PMA,  while  other  CD2 
antibodies fail to have such an effect. One CD2 antibody that is mitogenic in the 
presence of PMA is the classical E-receptor antibody, 9.6. This antibody sees a 
determinant  near the SRBC binding site, and inhibits E-rosette formation (14). 
Similar data were obtained also with X 11, another T111 antibody. Three other 
antibodies  of the  Till-like  reaction  type (7),  i.e.  the  antibodies  BMA  0110, 
OKT11, and T11, are not mitogenic in the presence of PMA, however (Table 
I). 
The third CD2 antibody found to be mitogenic in the presence of PMA is the 
VIT 13 antibody, directed against a determinant of the E-receptor only displayed 
by activated  but  not  by resting  T  cells.  Interestingly,  the  expression  of this 
epitope  or  its  surface  accessibility  to  VIT13  is  not  only  induced  after  lectin 
activation (13) but also by PMA treatment (Fig. 2). 
Simultaneous  triggering  of the  9.6  or  Xll,  and  VIT13  epitopes  by  the 
respective antibodies also induces T  cells to proliferate in the absence of PMA 
(Table I). Measurements of cytoplasmic Ca  ++ levels indicated, however, that the 
mechanisms are different for these two systems of T  cell stimulation via the CD2 
structure. 
When using the Quin2 fluorescence indicator,  we observed, like others, that 
Con A  rapidly elevates intracellular  Ca  ++ levels (Fig.  3, Table IV). We showed, 
to our knowledge for the first time, that a  nonmitogenic CD3 mAb (VIT3) (4) 
very efficiently elevates free cytoplasmic Ca  ++ in blood T  lymphocytes. 
In contrast to that, none of the CD2 antibodies under study led to detectable 
changes of intracellular  Ca ++ levels. More important,  this held even true when 
they were added to T  cells together with PMA, in spite of the fact that three of 
them were comitogenic with PMA. 
CD2 antibody-induced  increases of intracellular  Ca  ++ levels were, however, 
detectable after the combined addition of 9.6 or X11 plus VIT13 (Fig. 3, Table 
IV). Under these conditions, resting T  cells were stimulated to proliferate in the 
absence of PMA as well. 
The mitogenic effect and the Ca  ++ increase induced by the combination of the 
two CD2 antibodies 9.6 plus VIT13 resembles the observations of Weiss et al. 
(9) with antibody combinations of T 112 plus T 113 type. 
The mitogenic effect of certain CD2 antibodies in the presence of PMA recalls 
the findings (2-4) with soluble, not surface-presented CD3 antibodies, which are 
not mitogenic per se but can activate T  cells together with PMA. 
Using  OKT3  and  PMA,  other  authors  (29-31)  recently  distinguished  two 
distinct steps in the activation of Jurkat cells. They showed that the addition of 
OKT3  leads  to  the  generation  of inositol  triphosphate,  followed by a  rapid 
increase of cytoplasmic Ca  ++.  For further  activation  and the induction  of IL-2 
and IFN-7 production, a second signal was needed, which they could trigger by 
adding PMA. 
On the basis of these results, and in view of the fact that PMA directly activates 
the protein kinase C (32, 33), a highly Ca++-dependent enzyme, Imboden et al. HOLTER  ET  AL.  661 
(10) suggested that the increase in Ca  ++ plays a crucial role in antigen-receptor- 
mediated activation. 
For the activation of T  cells  via the CD2 structure, the so-called alternative 
pathway of T  cell activation, the situation seems to be  more complex.  It can 
occur concomitant with (two CD2  antibodies), or in the absence of (one CD2 
antibody plus PMA) detectable Ca  ++ responses. 
We cannot formally exclude the possibility that 9.6 or VIT 13 antibodies alone 
still lead to a Ca  ++ influx too small to be detected by our method. In view of the 
readily observed Ca  ++ responses to the other agents, however, we consider it to 
be unlikely. 
The  other  explanation  for  the  observed  induction of proliferation  in  the 
absence of Ca  ++ influx could be the fact that activation of the C kinase (e.g. by 
PMA) results in a dramatic increase of its affinity for Ca  ++ ions (34).  Thereby 
the enzyme, also under physiologic conditions, may not be dependent on addi- 
tional Ca  ++, either from intracellular stores or from the extracellular compart- 
ment (35).  While PMA may contribute to the induction of DNA replication via 
this mechanism, it is obviously not sufficient per se.  The mAbs against the CD2 
structure  used  must  deliver some  kind  of additional activation signal,  which 
seems, however, to be unrelated to Ca  ++ homeostasis. The underlying mecha- 
nisms may be similar to those involved in the recently reported (28) induction of 
T  cell proliferation by protein A  in the absence of measurable Ca  ++ increases. 
Regardless of the mechanism by which T  cells  triggered via  CD2  are  finally 
committed to proliferation, our data clearly show that a  single CD2  antibody 
already significantly alters the activation stage of a given resting T  cell. 
On the other hand, there is now some evidence that the combination of Ca  ++ 
elevation and protein C kinase activation does not necessarily lead to the initiation 
of  lymphocyte proliferation.  We  have,  for  instance,  seen  that  wheat  gernq 
agglutinin, which causes a  pronounced elevation of intracellular Ca  ++ (36 and 
Fischer,  unpublished  observations),  is  not  comitogenic with  PMA  (data  not 
shown). 
Summary 
We observed that certain E-receptor antibodies (CD2 antibodies) can induce 
proliferation of resting human T  cells in the presence of PMA, while other CD2 
antibodies fail  to  have  such  an  effect.  The  same  CD2  antibodies that  were 
mitogenic in the presence of PMA (9.6,  X1 l, VIT13), but not the nonreactive 
ones, were also able to induce T  cell proliferation via the so-called alternative 
pathway of T  cell activation, i.e., when added pairwise in certain combinations 
to T  cells in the absence of PMA. 
While the simultaneous addition of two comitogenic CD2 antibodies (9.6 or 
X 11 plus VIT 13) or the addition of a single nonmitogenic CD3 antibody (VIT3) 
led to a clearcut elevation of intracellular Ca  ++ levels, no such effect could be 
observed after the addition of one CD2 antibody alone. Even in the presence of 
PMA, one comitogenic CD2 antibody alone was unable to trigger a  significant 
Ca  ++ response, although this combination induced a proliferative response. 
These data indicate that, distinguishable by their influence on free cytoplasmic 
Ca  ++, there are two different mechanisms of T  cell activation via CD2.  While 662  T  CELL STIMULATION  VIA  THE ERYTHROCYTE  RECEPTOR 
simultaneous triggering with two antibodies leads to cell proliferation preceded 
by an increase of Ca  ++ levels, stimulation with one antibody plus PMA results in 
proliferation without  a  measurable  early Ca ++  response.  We  conclude  that  T 
cells  treated  by certain  CD2  antibodies  alone  already  recognize an  activation 
signal  probably  unrelated  to  Ca ++  homeostasis,  a  signal  that  can  further  be 
developed by PMA to result in a completely developed proliferative response. 
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